

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A
Amendment No.1

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 19, 2004

ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	0-12957 (Commission File Number)	22-2372868 (IRS Employer Identification)
---	--	--

685 Route 202/206, Bridgewater, New Jersey 08807
(Address of principal executive offices) (Zip Code)

(Registrant's telephone number, including area code: (908) 541-8600

(Former name or former address, if changed since last report)

Item 5. Other Events

On January 21, 2004, Enzon Pharmaceuticals, Inc. ("Enzon") filed a Current Report on Form 8-K (the "Original Form 8-K") to report a strategic partnership with Inex Pharmaceuticals Corporation ("INEX") to develop and commercialize INEX's proprietary oncology product Onco TCS. The disclosure set forth in Item 5 of the Original Form 8-K contained a typographical error stating that INEX received a US\$10 million up-front payment. The correct amount of the up-front payment was \$12 million, as was correctly set forth in the press release announcing the transaction issued by Enzon and filed as an exhibit to the Original Form 8-K.

This amendment continues to speak as of the date of the filing of the Original Current Report, and the Registrant has not updated the disclosures contained herein to reflect any events that occurred at a later date.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 03, 2004

By: /s/ Kenneth J. Zuerblis

Kenneth J. Zuerblis
Vice President, Finance and
Chief Financial Officer